Manufacturers start developing their trade names for a new drug during which of the following drug approval phases?

Question

Quizplus · Accepted Answer

A) In Clinical Phase 1 trials, manufacturers start developing their trade name for a new drug. Dosages and adverse effects are assessed on approximately 20-100 human volunteers initially, who have the disease or condition that the drug is being tested to treat. Doses are often subtherapeutic, but ascending (increasing) doses are used.

Manufacturers Start Developing Their Trade Names for a New Drug